Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 plus imatinib in metastatic or unresectable GIST after failure of imatinib, sunitinib and regorafenib
KCT0003086Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab, imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Started Feb 2019; status: completed.
02
Drugs
spartalizumabimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on KCT0003086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003086.